We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
Other
from Section III - Ovarian Cancer
Published online by Cambridge University Press: 20 July 2023
The management of patients with platinum-resistant recurrent epithelial ovarian cancer (EOC) poses a significant challenge. Traditionally treatment has involved the use of non-platinum chemotherapeutic agents, including PEGylated liposomal doxorubicin (PLD), topotecan, gemcitabine, and paclitaxel, used as monotherapy with response rates of 10–15%, progression-free survival (PFS) of three to four months and overall survival (OS) of approximately 12 months [1]. These agents have had limited efficacy and failed to demonstrate a meaningful OS benefit at the risk of chemotherapy toxicity. Through advancements in integrated genomic analysis, an increased understanding of the underlying molecular characteristics of EOC has led to the development of various molecularly targeted strategies designed to advance the field beyond single agent chemotherapy.
To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Find out more about the Kindle Personal Document Service.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.
